TeriflunomideIntervention1 paperPubChemChEBICWMHC, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.About aging: trials about aging, of every trial that tests the drug for any use.2 trials, none about agingTrial sponsorsSanofiCompany1 trialPhase 2128 peopleLatestNov 2025: 0Dec 2025: 0Jan 2026: 0Feb 2026: 0Mar 2026: 0Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 1Aug 2026: 0Sep 2026: 0Oct 2026: 01 in 12 monthsInflammopharmacology·Jul 28Immunometabolic reprogramming in multiple sclerosis: from pathogenic amplifier to therapeutic target in neuroinflammation and remyelinationReviewInflammationPaperBreast Disease·Apr 27Mini review: The FDA-approved prescription drugs that target the MAPK signaling pathway in women with breast cancerReviewInterventionsPaper
Inflammopharmacology·Jul 28Immunometabolic reprogramming in multiple sclerosis: from pathogenic amplifier to therapeutic target in neuroinflammation and remyelinationReviewInflammationPaper
Breast Disease·Apr 27Mini review: The FDA-approved prescription drugs that target the MAPK signaling pathway in women with breast cancerReviewInterventionsPaper